Optiscan has been featured in Stockhead’s quarterly wrap article, highlighting ongoing regulatory progress, clinical momentum, and broader sector activity across ASX-listed healthcare companies.
The article outlines Optiscan’s submission of its U.S. FDA dossier for InSpecta, marking a significant milestone in advancing the company’s veterinary-focused imaging device toward commercialisation in the U.S. market.
It also explores continued progress across Optiscan’s broader pipeline, with clinical studies for the InVue precision surgery and InForm digital pathology platforms advancing across Australia and internationally. These include the scaling of the breast cancer study at Royal Melbourne Hospital, early-stage recruitment in the head and neck cancer study at St John of God Murdoch Hospital, and ongoing pathology validation work with Australian Clinical Labs.
The feature highlights preparations for upcoming U.S. clinical studies at the Mayo Clinic, with institutional pre-submission processes completed and study activation anticipated, supporting future FDA submissions for both devices.
In parallel, the article notes continued product development and refinement, alongside growing international engagement and increased visibility through awards recognition and media activity.
Read the full article here.
